Adenosine A1 receptor agonists as clinically viable agents for treatment of ischemic brain disorders.
作者信息
Bischofberger N, Jacobson K A, von Lubitz D K
机构信息
Gilead Sciences, Inc., Foster City, California 94404, USA.
出版信息
Ann N Y Acad Sci. 1997 Oct 15;825:23-9. doi: 10.1111/j.1749-6632.1997.tb48411.x.
Abstract
摘要
相似文献
1
Adenosine A1 receptor agonists as clinically viable agents for treatment of ischemic brain disorders.
Ann N Y Acad Sci. 1997 Oct 15;825:23-9. doi: 10.1111/j.1749-6632.1997.tb48411.x.
2
Essential role of adenosine, adenosine A1 receptors, and ATP-sensitive K+ channels in cerebral ischemic preconditioning.
Proc Natl Acad Sci U S A. 1995 May 9;92(10):4666-70. doi: 10.1073/pnas.92.10.4666.
3
Adenosine and cerebral ischemia: therapeutic future or death of a brave concept?
Eur J Pharmacol. 1999 Jan 15;365(1):9-25. doi: 10.1016/s0014-2999(98)00788-2.
4
Adenosine A2A receptors and neuroprotection.
Ann N Y Acad Sci. 1997 Oct 15;825:30-48. doi: 10.1111/j.1749-6632.1997.tb48412.x.
5
Adenosine and cerebral ischemia: therapeutic future or death of a brave concept?
Eur J Pharmacol. 1999 Apr 23;371(1):85-102. doi: 10.1016/s0014-2999(99)00135-1.
6
Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative diseases.
Ann N Y Acad Sci. 1999;890:79-92. doi: 10.1111/j.1749-6632.1999.tb07983.x.
7
Adenosine A3 receptor stimulation and cerebral ischemia.
Eur J Pharmacol. 1994 Sep 22;263(1-2):59-67. doi: 10.1016/0014-2999(94)90523-1.
8
[Comparative characteristics of A1-receptor agonists as neuroprotective agents].
Eksp Klin Farmakol. 2001 Sep-Oct;64(5):19-22.
9
Therapeutic potential for adenosine receptor activation in ischemic brain injury.
J Neurotrauma. 1992 May;9 Suppl 2:S563-77.
10
Adenosine A1 receptor activation preferentially protects cultured cerebellar neurons versus astrocytes against hypoxia-induced death.
Mol Chem Neuropathol. 1997 Jun;31(2):119-33. doi: 10.1007/BF02815237.
引用本文的文献
1
Activation of Adenosine A Receptor in Ischemic Stroke: Neuroprotection by Tetrahydroxy Stilbene Glycoside as an Agonist.
Antioxidants (Basel). 2021 Jul 12;10(7):1112. doi: 10.3390/antiox10071112.
2
Hypothalamic or Extrahypothalamic Modulation and Targeted Temperature Management After Brain Injury.
Ther Hypothermia Temp Manag. 2017 Sep;7(3):125-133. doi: 10.1089/ther.2017.0003. Epub 2017 May 3.
3
Translating drug-induced hibernation to therapeutic hypothermia.
ACS Chem Neurosci. 2015 Jun 17;6(6):899-904. doi: 10.1021/acschemneuro.5b00056. Epub 2015 Apr 8.
4
Altered thermoregulation via sensitization of A1 adenosine receptors in dietary-restricted rats.
Psychopharmacology (Berl). 2010 Apr;209(3):217-24. doi: 10.1007/s00213-010-1778-y. Epub 2010 Feb 26.
5
Neuroprotection by adenosine in the brain: From A(1) receptor activation to A (2A) receptor blockade.
Purinergic Signal. 2005 Jun;1(2):111-34. doi: 10.1007/s11302-005-0649-1. Epub 2005 Mar 17.
6
NMDA receptor-mediated extracellular adenosine accumulation is blocked by phosphatase 1/2A inhibitors.
Brain Res. 2007 Jun 25;1155:116-24. doi: 10.1016/j.brainres.2007.04.057. Epub 2007 May 4.
7
The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity.
J Neurosci. 2002 Oct 15;22(20):9122-33. doi: 10.1523/JNEUROSCI.22-20-09122.2002.
8
Seizure activity produces differential changes in adenosine A1 receptors within rat hippocampus.
Neurochem Res. 2001 Mar;26(3):225-30. doi: 10.1023/a:1010912516299.
9
Direct measurement of adenosine release during hypoxia in the CA1 region of the rat hippocampal slice.
J Physiol. 2000 Jul 1;526 Pt 1(Pt 1):143-55. doi: 10.1111/j.1469-7793.2000.00143.x.
10
Protection against ischemic damage by adenosine amine congener, a potent and selective adenosine A1 receptor agonist.
Eur J Pharmacol. 1999 Mar 26;369(3):313-7. doi: 10.1016/s0014-2999(99)00073-4.
本文引用的文献
1
Species Differences in Ligand Affinity at Central A-Adenosine Receptors.
Drug Dev Res. 1994 Sep;33(1):51-59. doi: 10.1002/ddr.430330109.
2
N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects.
J Med Chem. 1999 Sep 9;42(18):3463-77. doi: 10.1021/jm960682u.
3
Postischemic administration of adenosine amine congener (ADAC): analysis of recovery in gerbils.
Eur J Pharmacol. 1996 Dec 5;316(2-3):171-9. doi: 10.1016/s0014-2999(96)00667-x.
4
Adenosine receptor ligands: differences with acute versus chronic treatment.
Trends Pharmacol Sci. 1996 Mar;17(3):108-13. doi: 10.1016/0165-6147(96)10002-x.
5
Reduction of postischemic brain damage and memory deficits following treatment with the selective adenosine A1 receptor agonist.
Eur J Pharmacol. 1996 Apr 29;302(1-3):43-8. doi: 10.1016/0014-2999(96)00101-x.
6
The A3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells.
J Biol Chem. 1993 Aug 15;268(23):16887-90.
7
Chronic administration of selective adenosine A1 receptor agonist or antagonist in cerebral ischemia.
Eur J Pharmacol. 1994 Apr 21;256(2):161-7. doi: 10.1016/0014-2999(94)90241-0.
8
Chronic adenosine A1 receptor agonist and antagonist: effect on receptor density and N-methyl-D-aspartate induced seizures in mice.
Eur J Pharmacol. 1994 Feb 21;253(1-2):95-9. doi: 10.1016/0014-2999(94)90762-5.
9
Adenosine: a prototherapeutic concept in neurodegeneration.
Ann N Y Acad Sci. 1995 Sep 15;765:163-78; discussion 196-7. doi: 10.1111/j.1749-6632.1995.tb16573.x.
10
Endogenously released adenosine regulates excitability in the in vitro hippocampus.
Epilepsia. 1980 Oct;21(5):541-8. doi: 10.1111/j.1528-1157.1980.tb04305.x.
Zotero 插件